Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD

Buhl, Roland; Dunn, Leonard; Disdier, Carlos; Lassen, Cheryl; Amos, Carolynn; Henley, Michael V.; Krämer, Benjamin

doi:10.1183/09031936.00191810

Cited by 130 publications

(109 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12 A blinded 12-week study in 1,598 patients comparing indacaterol 150 µg with tiotropium, in which treatment assignment was blinded, found that although the two treatments had closely similar bronchodilator effects (on trough FEV 1), indacaterol had a statistically significantly better effect on breathlessness (TDI scores), use of as-needed salbutamol, and health status (SGRQ scores). 42 On the other hand, tiotropium has established efficacy in reducing COPD exacerbations, 38,39 while the efficacy of indacaterol in this respect has not yet been fully investigated.…”

Section: Place Of Indacaterol In Treatment Algorithmmentioning

confidence: 99%

Efficacy of indacaterol in the treatment of patients with COPD

Jones

Barnes

Vogelmeier

et al. 2011

Primary Care Respiratory Journal

View full text Add to dashboard Cite

Effective bronchodilation is an important part of the management of patients with chronic obstructive pulmonary disease (COPD) and can improve breathlessness and ability to undertake physical activities. Indacaterol is a new once-daily, long-acting inhaled bronchodilator for COPD. We review here the efficacy of indacaterol as a bronchodilator, including its impact upon symptoms and health status. The evidence reviewed comprises four placebo-controlled clinical studies of indacaterol treatment, three of which included treatment arms with one of the other long-acting inhaled bronchodilators (once-daily tiotropium or twice-daily salmeterol or formoterol), in 4,833 patients with moderate-to-severe COPD. Indacaterol had a bronchodilator effect significantly greater than formoterol and salmeterol, and similar to tiotropium. Its effect on symptoms and health status was similar or significantly greater than the other bronchodilators. The safety profile was similar to placebo. Once-daily indacaterol is an effective and beneficial maintenance bronchodilator treatment for patients with moderate-to-severe COPD.

show abstract

Section: Place Of Indacaterol In Treatment Algorithmmentioning

confidence: 99%

Efficacy of indacaterol in the treatment of patients with COPD

Jones

Barnes

Vogelmeier

et al. 2011

Primary Care Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…QVA149 is a novel, inhaled, once-daily dual bronchodilator combining a fixed-dose of the LABA indacaterol and the LAMA glycopyrronium (NVA237), in development as a maintenance treatment for COPD. Both components of QVA149 are approved as single agents for the treatment of moderate-to-severe COPD, and their efficacy and safety has been demonstrated in large, randomised phase III studies [12][13][14][15][16][17][18][19]. Pivotal phase III studies have recently demonstrated the efficacy and safety profiles of once-daily QVA149 in patients with moderate-to-very severe COPD [20][21][22].…”

Section: Introductionmentioning

confidence: 99%

Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study

Decramer²,

et al. 2013

View full text Add to dashboard Cite

We evaluated the effect of QVA149, a dual bronchodilator combining indacaterol and glycopyrronium, on direct patient-reported dyspnoea in patients with moderate-to-severe chronic obstructive pulmonary disease.In this multicentre, blinded, double-dummy, three-period crossover study, 247 patients were randomised to once-daily QVA149 110/50 mg, placebo or tiotropium 18 mg. Superiority of QVA149 versus placebo (primary objective) and tiotropium (secondary objective) was assessed for improvement in dyspnoea via the self-administered computerised (SAC) version of the Baseline and Transition Dyspnoea Index after 6 weeks. Secondary end-points included lung function, rescue medication use and safety.After 6 weeks, the SAC Transition Dyspnoea Index total score was significantly higher with QVA149 versus placebo (least squares mean (LSM) treatment difference 1.37, p,0.001) and tiotropium (LSM treatment difference 0.49, p50.021). QVA149 provided significant improvements in lung function, with higher forced expiratory volume in 1 s area under the curve from 0-4 h post-dose versus placebo and tiotropium at day 1 and week 6 (all p,0.001). Rescue medication use was significantly lower with QVA149 versus placebo (p,0.001) and tiotropium (p50.002). All treatments were well tolerated.Once-daily QVA149 provided superior improvements in patient-reported dyspnoea and lung function versus placebo and tiotropium. These benefits were associated with improvements in other symptoms and reduced use of rescue medication. @ERSpublications Two different bronchodilators in a single inhaler were effective in relieving patient-reported dyspnoea in COPD

show abstract

“…Kategori A'da yer alan stabil KOAH hastalarına farmakolojik tedavi olarak ilk tercih edilecek ilaçlar gerektiği durumda kısa etkili bronkodilatörlerdir (kısa etkili (8,10). Bu iki uzun etkili bronkodilatör ilacın plaseboyla karşılaştırıldığı INHANCE çalışmasında 12. haftada trough FEV 1 değerinde indakaterol kolunda 180 mL, tiotropium kolunda 140 mL, artışla plaseboyla karşılaştırıldığın-da anlamlı iyileşme saptandı (11).…”

Section: Introductionunclassified

New bronchodilators and combinations in COPD treatment

Günay¹,

Sarıaydın²,

Demirci³

2016

Tuberk Toraks

View full text Add to dashboard Cite

KOAH tedavisinde yeni bronkodilatörler ve kombinasyonları ÖZET KOAH tedavisinde yeni bronkodilatörler ve kombinasyonları Bronkodilatör ilaçlar, kronik obstrüktif akciğer hastalığı (KOAH) ve astım tedavisinde yaygın olarak kullanılan tedavilerdir. Bronkodilatasyon için hem sempatik sistem (özellikle beta-2 reseptörler) aktivasyonu hem de parasempatik sistemin inhibisyonu (antimuskarinik etki) mekanizmalarından faydalanılır. KOAH'ta kullanılan bronkodilatör tedavilerde, 20 yılı aşkın süredir belirgin bir değişiklik olmamıştır. Ancak son yıllarda yeni, ultra uzun etkili bronkodilatör ilaçların geliştirilmesi ile stabil KOAH tedavisinde günde tek doz inhaler tedavi uygulamaları gündeme geldi. Bu derlemede literatürde bildirilen çalışmaların sonuçları ışığında yeni, ultra uzun etkili beta-2 agonist ve antikolinerjik bronkodilatör tedavilerin etkinlikleri tartışılacaktır.Anahtar kelimeler : Bronkodilatör, antikolinerjik, ultra uzun etki, KOAH, astım SUMMARY New bronchodilators and combinations in COPD treatment Bronchodilator drugs are widely used therapeutic agents for treatment of asthma and chronic obstructive pulmonary disease (COPD). In order to mantain bronchodilation, both sympathetic system (particularly beta-2 receptors) activation and parasympathetic system inhibition (antimuscarinic effect) mechanisms are utilized. Over 20 years, there were no significant changes in bronchodilator therapy in obstructive pulmonary diseases. In recent years, however, after the development of new ultra long acting bronchodilator drugs, a single dose inhaler treatments per day in the treatment of stable COPD became a current issue. In this review, with the guidence of the current literature, the effects of new beta-2 agonists and anticholinergic bronchodilators will be discussed.Key words : Bronchodilator, anticholinergic, ultra GİRİŞKronik obstrüktif akciğer hastalığı (KOAH)'ında ilaç tedavisi önemli bir yer tutmaktadır. KOAH alevlenmesinin tedavisinde son 20 yılda belirgin bir değişik-lik olmamıştır. Ancak, stabil KOAH tedavisi için yeni bronkodilatör ajanlar geliştirilmiş ve tüm dünyada ve ülkemizde de kullanıma girmeye başlamıştır.KOAH tedavisinde amaç semptomların giderilmesi, egzersiz toleransının ve sağlık durumunun iyileştiril-mesi) ve gelecek risklerin azaltılmasıdır (atakların önlenmesi ve tedavisi, hastalığın ilerlemesinin önlen-mesi ve mortalitenin azaltılması) (1,2). Geliştirilecek ilaçların da bu amaçlara yönelik etkilerinden faydalanılmaktadır.Bronkodilatör, zorlu ekspiratuvar birinci saniyedeki hacim (FEV 1 ) artışı veya diğer spirometrik parametrelerde değişikliğe neden olan, genellikle bu etkilerini hava yolu düz kas tonunu değiştirerek gerçekleştiren ilaçlar için kullanılan bir terimdir (1,3). Bu ilaçlar akciğerin boşalmasını iyileştirir, istirahat ve egzersiz süresince dinamik hiperinflasyonu azaltır (1,4,5). Böylece egzersiz performansında iyileşmeye neden olurlar (1).İnhaler bronkodilatör ilaçlar etki süresine göre kısa etkili (short-acting) veya uzun etkili (long-acting) bronkodilatörler olarak iki...

show abstract

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD

Cited by 130 publications

References 25 publications

Efficacy of indacaterol in the treatment of patients with COPD

Efficacy of indacaterol in the treatment of patients with COPD

Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study

New bronchodilators and combinations in COPD treatment

Contact Info

Product

Resources

About